Clinical trial: Irsogladine maleate, a mucosal protective drug, accelerates gastric ulcer healing after treatment for eradication of Helicobacter pylori infection - The results of a multicentre, double-blind, randomized clinical trial (IMPACT study)

Alimentary Pharmacology and Therapeutics

Volumn 31, Issue 8, 2010, Pages 824-833

  Hiraishi, H ^a   Haruma, K ^b   Miwa, H ^c   Goto, H ^d  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

^b KAWASAKI MEDICAL SCHOOL   (Japan)

^c HYOGO COLLEGE OF MEDICINE   (Japan)

^d NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; IRSOGLADINE MALEATE; LANSOPRAZOLE; PLACEBO;

ABDOMINAL DISTENSION; ADULT; ARTICLE; BLOOD CELL COUNT; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENTERITIS; ERADICATION THERAPY; HELICOBACTER INFECTION; HUMAN; INTESTINE ISCHEMIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; SIDE EFFECT; STOMACH CANCER; STOMACH ULCER; STOMATITIS; ULCER HEALING; URTICARIA;

ADULT; ANTI-ULCER AGENTS; DOUBLE-BLIND METHOD; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; STOMACH ULCER; TREATMENT OUTCOME; TRIAZINES; WOUND HEALING; YOUNG ADULT;

EID: 77949725649     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04250.x     Document Type: Article

References (45)

1. The Guideline Committee of the Japanese Society for Helicobacter Research. Guidelines for diagnosis and treatment. Helicobacter Res 2000 4 : 444 454.
2. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002 16 : 167 180.
3. Asaka M, Sugiyama T, Kato M, et al. A multicenter, double-blind study on triple therapy with lansoprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients. Helicobacter 2001 6 : 254 261.
4. Miwa H, Sasaki N, Sugano K, et al. Recurrent peptic ulcers in patients following successful Helicobacter pylori eradication: a multicenter study of 4940 patients. Helicobacter 2004 9 : 9 16.
5. Leodolter A, Kulig M, Brasch H, Meyer-Sabellek W, Willich SN, Malfertheiner P. A meta-analysis comparing eradication, healing and relapse rates in patients with Helicobacter pylori-associated gastric or duodenal ulcer. Aliment Pharmacol Ther 2001 15 : 1949 1958.
6. Annibale B, D'Ambra G, Luzzi I, et al. Does pretreatment with omeprazole decrease the chance of eradication of Helicobacter pylori in peptic ulcer patients? Am J Gastroenterol 1997 92 : 790 794.
7. Okada M, Oki K, Shirotani T, et al. A new quadruple therapy for the eradication of Helicobacter pylori. Effect of pretreatment with omeprazole on the cure rate. J Gastroenterol 1998 33 : 640 645.
8. Hosking SW, Ling TK, Chung SC, et al. Duodenal ulcer healing by eradication of Helicobacter pylori without anti-acid treatment; randomized controlled trial. Lancet 1994 343 : 508 510.
9. Gisbert JP, Pajares JM. Systematic review and meta-analysis: is 1-week proton pump inhibitor-based triple therapy sufficient to heal peptic ulcer? Aliment Pharmacol Ther 2005 21 : 795 804.
10. Atherton JC. Can peptic ulcers be healed with 7 days of proton-pump-inhibitor-based triple therapy? Nat Clin Pract Gastroenterol Hepatol 2005 2 : 346 347.
11. Watanabe Y, Kawai K. Descriptive and analytical epidemiology of peptic ulcer disease in Japan. Gastroenterol Jpn 1991 26 (Suppl 3 258 261.
12. Lai KC, Hui WM, Wong BC, Hu WH, Lam SK. Ulcer-healing drugs are required after eradication of Helicobacter pylori in patients with gastric ulcer but not duodenal ulcer haemorrhage. Aliment Pharmacol Ther 2000 14 : 1071 1076.
13. Higuchi K, Fujiwara Y, Tominaga K, et al. Is eradication sufficient to heal gastric ulcers in patients infected with Helicobacter pylori? A randomized, controlled, prospective study. Aliment Pharmacol Ther 2003 17 : 111 117.
14. Perez Aldana L, Kato M, Nakagawa S, et al. The relationship between consumption of antimicrobial agents and the prevalence of primary Helicobacter pylori resistance. Helicobacter 2002 7 : 306 309.
15. Osato MS, Reddy R, Reddy SG, et al. Pattern of primary resistance of Helicobacter pylori to metronidazole or clarithromycin in the United States. Arch Intern Med 2001 161 : 1217 1220.
16. 2-receptor antagonist until assessment of Helicobacter pylori eradication can reduce recurrence of peptic ulcer after successful eradication of the organism; prospective randomized controlled trial. J Gastroenterol Hepatol 2006 21 : 1048 1053.
17. 14C-urea breath test. Am J Gastroenterol 1996 91 : 89 92.
18. 14C-urea breath test by a pH-dependent mechanism. Am J Gastroenterol 1997 92 : 446 450.
19. Laine L, Estrada R, Trujillo M, Knigge K, Fennerty MB. Effect of proton pump inhibitor therapy on diagnostic testing for Helicobacter pylori. Ann Intern Med 1998 129 : 547 550.
20. 13C-urea breath test results. Am J Gastroenterol 1998 93 : 1297 1299.
21. Kyoi T, Noda K, Oka M, Ukai Y. Irsogladine, an anti-ulcer drug, suppresses superoxide production by inhibiting phosphodiesterase type 4 in human neutrophils. Life Sci 2004 76 : 71 83.
22. Ueda F, Kameda U, Yamamoto O, Shibata Y. Beta-adrenergic regulation of gap-junctional intercellular communication in cultured rabbit gastric epithelial cells. J Pharmacol Exp Ther 1994 271 : 397 402.
23. Kyoi T, Oka M, Noda K, Ukai Y. Irsogladine prevents monochloramine- induced gastric mucosal lesions by improving the decrease in mucosal blood flow due to the disturbance of nitric oxide synthesis in rats. J Pharmacol Sci 2003 93 : 314 320.
24. Sato M, Manabe N, Hata J, et al. Effect of irsogladine maleate on NSAID-induced reduction of gastric mucosal blood flow in anesthetized dogs. Digestion 2009 79 : 73 8.
25. Tatsumi Y, Tanino M, Kodama T, et al. Irsogladine maleate may preserve gastric mucosal hydrophobicity against ethanol in phospholipids independent way in rats. Jpn J Pharmacol 1998 77 : 293 299.
26. Zhang X, Tajima K, Kageyama K, Kyoi T. Irsogladine maleate suppresses indomethacin-induced elevation of proinflammatory cytokines and gastric injury in rats. World J Gastroenterol 2008 14 : 4784 4790.
27. Masuyama H, Ishida M, Morita K, et al. An open-label, multi-center study of irsogladine maleate for gastric ulcer healing after eradication of Helicobacter pylori. Ther Res 2008 29 : 415 422.
28. Marshall BJ, Warren JR, Francis GJ, et al. Rapid urease test in the management of Campylobacter pyloridis-associated gastritis. Am J Gastroenterol 1987 82 : 200 210.
29. 13C-urea breath test for diagnosis of Helicobacter pylori infection in Japan. J Gastroenterol 1998 33 : 6 13.
30. Nemoto S, Chino F, Ohkubo H, et al. Results of the drug use result survey of triple therapy with lansoprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in patients with peptic ulcer. J Clin Ther Med 2006 22 : 21 30.
31. Tahir H, Sumii K, Haruma K, et al. A statistical evaluation on the age and sex distribution of basal serum gastrin and gastric acid secretion in subjects with or without peptic ulcer disease. Hiroshima J Med Sci 1984 33 : 125 130.
32. Feldman M, Richardson CT, Lam SK, Samloff IM. Comparison of gastric acid secretion rates and serum pepsinogen I and II concentrations in Occidental and Oriental duodenal ulcer patients. Gastroenterology 1988 95 : 630 635.
33. Robles-Jara C, Robles-Medranda C, Moncayo M, Landivar B, Parrales J. Is a 7-day Helicobacter pylori treatment enough for eradication and inactivation of gastric inflammatory activity? World J Gastroenterol 2008 14 : 2838 2843.
34. Graham DY. Efficient identification and evaluation of effective Helicobacter pylori therapies. Clin Gastroenterol Hepatol 2009 7 : 145 148.
35. McGowan CC, Cover TL, Blaser MJ. The proton pump inhibitor omeprazole inhibits acid survival of Helicobacter pylori by a urease-independent mechanism. Gastroenterology 1994 107 : 1573 1578.
36. Sharma BK, Santana IA, Wood EC, et al. Intragastric bacterial activity and nitrosation before, during, and after treatment with omeprazole. Br Med J 1984 289 : 717 719.
37. Iwahi T, Satoh H, Nakao M, et al. Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori. Antimicrob Agents Chemother 1991 35 : 490 496.
38. Rektorschek M, Weeks D, Sachs G, Melchers K. Influence of pH on metabolism and urease activity of Helicobacter pylori. Gastroenterology 1998 115 : 628 641.
39. 13C-urea breath test for the diagnosis of Helicobacter pylori infection. J Gastroenterol 2003 38 : 937 941.
40. Okabe S, Takeuchi K, Ishihara Y, Kunimi H. Effect of 2,4-diamino-6-(2,5- dichlorophenyl)-s-triazine maleate (MN-1695) on gastric secretion and on experimental gastric ulcers in rats. Pharmacokinetics 1982 24 : 683 689.
41. Okabe S, Takeuchi K, Okamoto N, Hirosawa R. Effect of 2,4-diamino-6-(2,5- dichlorophenyl)-s-triazine maleate (MN-1695) on gastric secretion and on experimental gastric ulcers in rats (2). Comparison with other antiulcer drugs. Pharmacokinetics 1984 27 : 79 86.
42. Huang JQ, Sridhar S, Chen Y, Hunt RH. Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology 1999 114 : 1169 1179.
43. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001 345 : 784 789.
44. Fukase K, Kato M, Kikuchi S, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 2008 372 : 392 397.
45. Sung JJY, Chung SCS, Ling TKW, et al. Antibacterial treatment of gastric ulcers associated with Helicobacter pylori. N Engl J Med 1995 332 : 139 142.